Double hit and double expressors in lymphoma: Definition and treatment

Emerging biologic subsets and new prognostic markers are significantly and adversely affecting curability after standard chemoimmunotherapy for aggressive B‐cell lymphomas. The identification of concurrent MYC and B‐cell CLL/lymphoma 2 (BCL2) deregulation, whether at a genomic or protein level, has opened a new era of investigation within the most common subtype of aggressive B‐cell lymphomas. Double‐hit lymphoma (DHL), defined as a dual rearrangement of MYC and BCL2 and/or B‐cell CLL/lymphoma 6 (BCL6) genes, is an uncommon subset accounting for 5% to 7% of all diffuse large B‐cell lymphomas (DLBCLs), and long‐term survivors are rare. Double‐expressor lymphoma (DEL), defined as overexpression of MYC and BCL2 proteins not related to underlying chromosomal rearrangements, is not a distinct entity in the current World Health Organization classification but accounts for 20% to 30% of DLBCL cases and also has poor outcomes. There are many practical considerations related to identifying, determining the prognosis of, and managing DHL and DEL.

[1]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[2]  A. Zetterberg,et al.  Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[4]  S. Lowe,et al.  Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. , 2001, Blood cells, molecules & diseases.

[5]  R. Fisher,et al.  The epidemiology of non-Hodgkin's lymphoma , 2004, Oncogene.

[6]  Ryan T. Phan,et al.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells , 2004, Nature.

[7]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[8]  F. Jardin,et al.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.

[9]  M. Dimopoulos,et al.  CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group , 2007, Cancer journal.

[10]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[11]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[12]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[13]  B. Hoffman,et al.  Apoptotic signaling by c-MYC , 2008, Oncogene.

[14]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[15]  S. Yoon,et al.  MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.

[16]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[17]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[18]  N. Nakamura,et al.  Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations , 2009, Haematologica.

[19]  Aggressive lymphomas. , 2010, The New England journal of medicine.

[20]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Basso,et al.  BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. , 2010, Advances in immunology.

[22]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Hammerman,et al.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2010, Cancer.

[24]  L. Rimsza,et al.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma , 2010, Haematologica.

[25]  F. Jardin,et al.  Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. , 2011, The Lancet. Oncology.

[26]  W. Chan,et al.  Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2011, British journal of haematology.

[27]  A. Rosenwald,et al.  MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .

[28]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Lauritzen,et al.  Double‐hit BCL2/MYC translocations in a consecutive cohort of patients with large B‐cell lymphoma – a single centre's experience , 2012, European journal of haematology.

[30]  K. Basso,et al.  Roles of BCL6 in normal and transformed germinal center B cells , 2012, Immunological reviews.

[31]  Ryan D. Morin,et al.  BCL2 mutations in diffuse large B-cell lymphoma , 2012, Leukemia.

[32]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[34]  J. Briones,et al.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.

[35]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[36]  R. Spang,et al.  Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.

[37]  Michael L. Wang,et al.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.

[38]  D. Huang,et al.  Targeting BCL2 for the treatment of lymphoid malignancies. , 2014, Seminars in hematology.

[39]  P. Juszczyński,et al.  MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. , 2014, Biochimica et biophysica acta.

[40]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[41]  S. Swerdlow Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. , 2014, Hematology. American Society of Hematology. Education Program.

[42]  S. Schuster,et al.  ‘Double‐Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients , 2014, British journal of haematology.

[43]  E. Campo,et al.  MYC alterations in diffuse large B-cell lymphomas. , 2015, Seminars in hematology.

[44]  D. Scott Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic? , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[45]  A. Rosenwald,et al.  Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations , 2015, The American journal of surgical pathology.

[46]  K. Young,et al.  MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma , 2015, Oncotarget.

[47]  S. Barrans,et al.  The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit , 2015, The journal of pathology. Clinical research.

[48]  C. Copie-Bergman,et al.  MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.

[49]  N. Gebauer,et al.  TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations , 2015, Leukemia & lymphoma.

[50]  K. Basso,et al.  Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.

[51]  S. Schuster,et al.  Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis , 2015, British journal of haematology.

[52]  High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience , 2016 .

[53]  Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH , 2016 .

[54]  Sonali M. Smith,et al.  Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 , 2016, British journal of haematology.

[55]  A. Zelenetz,et al.  Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma , 2016, Cancer.

[56]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[57]  Ken H. Young,et al.  Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma , 2015, Oncotarget.

[58]  Scott E. Smith,et al.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable , 2016, British journal of haematology.

[59]  R. Gascoyne,et al.  Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. , 2016, Blood.

[60]  Scott E. Smith,et al.  Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 , 2016 .

[61]  J. Vose,et al.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Papenhausen,et al.  The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects , 2017, Genes.

[63]  Y. Oki,et al.  P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma , 2017, Modern Pathology.

[64]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[65]  L. Medeiros,et al.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma , 2017, Modern Pathology.

[66]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[67]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[68]  W. Chan,et al.  Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Leonard,et al.  Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Philipp W. Raess,et al.  Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma , 2018, Leukemia & lymphoma.

[71]  W. Chan,et al.  Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.